SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• A case report described the use of TREMFYA as a treatment of uveitis in a male patient with sarcoidosis-related panuveitis.¹

CLINICAL DATA

Case Report

Thomas et al (2020)¹ reported the use of TREMFYA in a 61-year-old Asian-Indian male patient with sarcoidosis-related panuveitis.

• The patient’s ocular disease had been minimal for several years, requiring only occasional limited courses of topical corticosteroids for flares of anterior uveitis. Inflammation in both eyes had been quiescent at his last evaluation 6 months prior.
• Patient had a long history of dermatologic disease with a presumptive diagnosis of plaque psoriasis since his 30s. Management of his severe cutaneous disease over the years included treatments such as methotrexate, infliximab, adalimumab, etanercept, hydroxychloroquine, secukinumab, and ustekinumab. The patient was later diagnosed with sarcoidosis in 2013. A skin biopsy in 2016 was also consistent with cutaneous sarcoidosis.
• The patient was started on TREMFYA 100 mg administered subcutaneously on weeks 0, 4 then every 8 weeks for his cutaneous disease. While on TREMFYA, he noted slight improvement in his cutaneous symptoms.
• The patient was on TREMFYA for 4 months prior to the onset of a uveitic flare in the right eye precipitated by a preceding cataract surgery, after which a course of oral corticosteroids was initiated. While the oral steroids improved the anterior chamber inflammation, persistent cystoid macular edema (CME) necessitated the addition of topical difluprednate (0.05%) 4 times a day to the right eye. Four months into the flare of the right eye, visual acuity had improved to 20/80, the anterior chamber inflammation had resolved, the vitritis had improved and the CME was largely gone, but the patient was still on difluprednate four times a day.
• Additionally, the nonsurgical left eye also experienced a flare 8 months into TREMFYA therapy with 1+ anterior chamber cell with a slight reduction in visual acuity to 20/50.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 10 February 2025.